New Peer-Reviewed Study Demonstrates Unique Method of Action for Immunovaccine’s Delivery Technology
Equities.com,
The Journal of Biomedical Science, an open access, peer-reviewed journal, published a study in its January 27, 2018, issue that…
Published Study Demonstrates the Association Between Immunovaccine’s Proprietary Immune-targeted Delivery Technology and Enhanced Efficacy in Slowing Tumor Progression
BioTech Gate,
HALIFAX, Nova Scotia, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncol…
Published Study Demonstrates the Association Between Immunovaccine’s (IMV)(IMMVF) Proprietary Immune-targeted Delivery Technology and Enhanced Efficacy in Slowing Tumor Progression
Equities.com,
Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF ), a clinical stage immuno-oncology company, today announced the publication of a…
Published Study Demonstrates the Association Between Immunovaccine's Proprietary Immune-targeted Delivery Technology and Enhanced Efficacy in Slowing Tumor Progression
Tucson News Now,
Study in the Journal of Biomedical Science Compared the Novel Mechanism of Action Underscoring the Company’s Immunotherapy…